VistaGen Therapeutics, Inc. ROIC

ROIC of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual ROIC for 2019 was 0.0% (a NaN% decrease from previous year)
  • Annual ROIC for 2018 was 0.0% (a NaN% decrease from previous year)
  • Twelve month ROIC ending December 30, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by NaN% year-over-year
Trailing ROIC for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of VistaGen Therapeutics, Inc.

Most recent ROICof VTGN including historical data for past 10 years.

Interactive Chart of ROIC of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0%
2019 0.0%
2018 0.0%
2017 0.0%
2016 0.0%
2015 0.0%
2014 0.0%
2013 0.0%
2012 0.0%
2011 0.0%
2010 0.0%

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.